Alexion Pharmaceuticals Stocks 2024

Alexion Pharmaceuticals Stocks

222 M

Alexion Pharmaceuticals Dividend yield

Ticker

ALXN

ISIN

US0153511094

WKN

899527

In 2024, Alexion Pharmaceuticals had 222 M outstanding stocks, a 0% change from the 222 M stocks in the previous year.

The Alexion Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2025e222
2024e222
2023e222
2022e222
2021e222
2020222
2019224.8
2018224.5
2017225.4
2016226.3
2015215.9
2014201.6
2013199.7
2012198.5
2011191.8
2010186.1
2009181.2
2008179.9
2007145.2
2006126.8
2005122.1
200486.5
200372.8
200272.6
200169.5

Alexion Pharmaceuticals Aktienanalyse

What does Alexion Pharmaceuticals do?

Alexion Pharmaceuticals Inc. is a US biotechnology company specializing in the development and commercialization of drugs for the treatment of rare diseases. It was founded in 1992 and is headquartered in Boston, Massachusetts. The history of Alexion began with the discovery of the protein C5a, which is responsible for the occurrence of inflammation. Alexion then developed the first medication, Soliris, specifically for the treatment of the rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is classified as a monoclonal antibody and inhibits the protein C5a, which is responsible for inflammation. Alexion's business model focuses primarily on developing drugs for rare diseases. These diseases are unprofitable for most major pharmaceutical companies because they have a small patient base. However, Alexion has begun to identify and develop drugs for such diseases that are tailored to these specific patients. Such drugs are not suitable for the majority of the patient population as they are very expensive. Alexion is divided into several divisions focused on the development and launch of drugs for specific diseases. The most well-known division is PNH, but the company has also developed drugs for rare hematological, nephrological, neurological, immunological, and metabolic diseases. Alexion has also developed the ability to bring drugs to market faster than other pharmaceutical companies by employing innovative clinical trial methods. In addition to Soliris, Alexion has developed other drugs such as Ultomiris, Strensiq, and Kanuma. Ultomiris is a successor to Soliris and is used to treat PNH and aHUS. Strensiq is used for patients with hypophosphatasia, while Kanuma was developed for patients with lysosomal storage diseases such as children with Gaucher disease or Fabry disease. Alexion also collaborates with other companies to develop and market drugs for rare diseases. The most well-known example is the collaboration with the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation to develop the drug ALXN1210, which Alexion hopes will surpass both Soliris and Ultomiris. The collaboration has the potential to provide groundbreaking treatment for PNH, aHUS, and other rare diseases. Overall, in recent years, Alexion Pharmaceuticals Inc. has become an important player in the market for rare diseases. The company has taken on challenging tasks by striving to uncover rare diseases and gaps and then finding new, unique solutions to treat these diseases. In the future, Alexion will continue its efforts in researching and developing drugs for rare diseases and will continue to provide innovative solutions and therapeutic approaches to improve the lives of patients. Alexion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Alexion Pharmaceuticals revenue by segment

In the annual report of the Alexion Pharmaceuticals share (US0153511094, 899527, ALXN), it breaks down its revenues into 1 segments: 1. Therapies. The Alexion Pharmaceuticals stock (WKN: 899527, ISIN: US0153511094, Ticker Symbol: ALXN) is a leading investment for investors interested in participating in the Health Care sector.

Stocks Details

Evaluating Alexion Pharmaceuticals's Shares Outstanding

Alexion Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Alexion Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Alexion Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Alexion Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Alexion Pharmaceuticals Stock

How many stocks are there of Alexion Pharmaceuticals?

The current number of stocks of Alexion Pharmaceuticals is 222 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Alexion Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Alexion Pharmaceuticals evolved in recent years?

The number of shares of Alexion Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Alexion Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Alexion Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Alexion Pharmaceuticals pay?

Over the past 12 months, Alexion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alexion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Alexion Pharmaceuticals?

The current dividend yield of Alexion Pharmaceuticals is .

When does Alexion Pharmaceuticals pay dividends?

Alexion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alexion Pharmaceuticals?

Alexion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Alexion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alexion Pharmaceuticals located?

Alexion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alexion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alexion Pharmaceuticals from 3/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.

When did Alexion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 3/28/2024.

What was the dividend of Alexion Pharmaceuticals in the year 2023?

In the year 2023, Alexion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Alexion Pharmaceuticals pay out the dividend?

The dividends of Alexion Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Alexion Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Alexion Pharmaceuticals

Our stock analysis for Alexion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alexion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.